光生物素探针对白血病患者c-myc和c-fos原癌基因表达水平的检测

Detection of c-myc and c-fos Proto-Oncogene Expression Level in Leukemia Patients with Photobiotin Labeled Probes

用国产光生物素标记探针,经RNA-DNA斑点杂交技术检测了41例白血病患者中c-myc和c-fos原癌基因的RNA表达水平。c-myc和c-fos的强阳性表达率分别为82.8%和76.6%,c-myc在急性白血病和慢性粒细胞白血病急变时表达水平明显高于慢性粒细胞白血病和慢性淋巴细胞白血病及对照组,化疗完全缓解后表达水平下降,而与FAB分型无关;c-fos在AML的M_4和M_5中表达水平明显增高。提示c-myc表达与细胞增殖潜能有关,能为诱导缓解治疗结果的预测提供有意义的临床和生物学方面的信息,c-fos反映细胞分化状态,可作为白血病亚型分类的辅助指标之一。同时,本研究还探讨了光生物素探针标记技术的优越性,操作简便,方法敏感,可代替放射性核素探针在一般实验室的常规实验和诊断之用。

The c-myc and c-fos proto-oncogenes were detected in forty-one leukemia patients by RNA-DNA dot blot hybridization with photobiotin probes. The results showed that the positive rate of c-myc and c-fos was 82. 8% and 76. 6%, respectively. Patients with acute leukemia and chronic myeloid leukemia with blast crisis have higher c-myc expression levels than those with chronic myeloid leukemia and control group. The c-myc expression level is unrelated to the FAB classification and decreased after complete remission. c-Fos level was especially high in M4 and M5 of acute myeloid leukemia. It is suggested that the RNA level of c-myc proto-oncogene is indication of the proliferative potential of cells. Hence, assessment of c-myc RNA levels may provide useful clinical and biological information regarding the probable outcome of remission by induction therapy. c-Fos, which reflects the state of cellular differentiation, it might be an additional marker for sub-classification of human leukemias. The study also showed that the photobiotin labeled probes can provide the sensitivity and simplicity of handling needed to replace radioactive probes in routine laboratory experiments and diagnostic assays.